Singapore Cell and Gene Centre (SCGC)

Overview

The Singapore Cell and Gene Centre (SCGC) is a Singapore-based research and development center focused on cell therapy and gene therapy approaches for degenerative diseases, including Parkinson's disease (PD). The center operates within Singapore's robust biotechnology ecosystem and collaborates with leading research institutions to advance regenerative medicine approaches["@astar"].

Company Information

Overview

The Singapore Cell and Gene Centre (SCGC) is a Singapore-based research and development center focused on cell therapy and gene therapy approaches for degenerative diseases, including Parkinson's disease (PD). The center operates within Singapore's robust biotechnology ecosystem and collaborates with leading research institutions to advance regenerative medicine approaches["@astar"].

Company Information

| Detail | Value |
|--------|-------|
| Headquarters | Singapore |
| Focus | Cell therapy, gene therapy, regenerative medicine |
| Type | Research institute / biotechnology center |
| Parent | A*STAR (Agency for Science, Technology and Research) |

Scientific Approach

SCGC focuses on developing cell-based and gene-based therapies with three primary modalities:

Cell Replacement Therapy

• Stem cell-derived dopaminergic neurons: Using pluripotent stem cells (embryonic stem cells and induced pluripotent stem cells) to generate dopamine-producing neurons for transplantation into PD patients
• The approach is based on the foundational work demonstrating that stem cell-derived dopamine neurons can reverse parkinsonism in animal models[@kriks2011]
• Clinical trials using cell therapy for PD have shown promise, with ongoing efforts to improve cell purity and survival[@barker2015]

Gene Therapy

• Viral vector-mediated gene delivery: Using adeno-associated virus (AAV) and lentiviral vectors to deliver therapeutic genes to the central nervous system
• Neurotrophic factor delivery: Delivery of GDNF, BDNF, and other neurotrophic factors to support neuron survival and function
• Gene editing approaches: CRISPR-based technologies for correcting genetic mutations in familial PD

Regenerative Medicine

• Tissue engineering: Development of biomaterial scaffolds for cell delivery and tissue repair
• 3D bioprinting: Emerging technologies for creating complex tissue constructs
• Organoid models: Development of brain organoids for disease modeling and drug screening

Parkinson's Disease Program

The Parkinson's disease program at SCGC encompasses multiple therapeutic approaches:

Dopaminergic Neuron Transplantation

• Derivation of dopamine neurons from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs)
• Protocols for generating midbrain dopamine neurons with proper subtype specification
• Optimization of transplantation procedures for maximum cell survival and integration

Neuroprotective Gene Therapy

• GDNF delivery: AAV-mediated delivery of glial cell line-derived neurotrophic factor for protecting dopaminergic neurons
• BDNF delivery: Brain-derived neurotrophic factor for supporting neuron survival
• NURR1 activation: Nuclear receptor-related 1 (NURR1) gene delivery to promote dopamine neuron function

Immune Modulation

• Approaches to reduce neuroinflammation in PD
• Modulation of microglia activation states
• Cytokine targeting strategies

Research Focus

| Area | Application | Status |
|------|-------------|--------|
| Stem cell therapy | Neuronal replacement | Preclinical/GLP |
| Gene editing | Disease modification | Research |
| Biomaterials | Cell delivery scaffolds | Development |
| Neurotrophins | Neuroprotection | Preclinical |
| Immunomodulation | Anti-inflammatory | Research |

Collaborations

SCGC works closely with Singapore's premier research institutions:

• A*STAR (Agency for Science, Technology and Research) — Primary parent organization providing funding and infrastructure
• National University of Singapore (NUS) — Collaboration on stem cell biology and neuroscience research
• Nanyang Technological University (NTU) — Engineering partnerships for biomaterials and device development
• Singapore Health Services (SingHealth) — Clinical translation and trial partnerships

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cell Therapy](/mechanisms/cell-therapy)
• [Stem Cell Therapy](/therapeutics/stem-cell-therapy)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Dopamine](/entities/dopamine)
• [A*STAR](/institutions/astar-singapore)

References